Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PYGM | P11217 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333486 | 0.88 | CDA (0.41) | CDAMAPTPYGMLMNAMTOR | |
| SCHEMBL31685741 | 0.87 | LGALS8 (0.35) | CDAMAPTTK2 | |
| SCHEMBL31685232 | 0.85 | CYP2C19 (0.40) | — | |
| SCHEMBL31685543 | 0.84 | UMPS (0.48) | — | |
| SCHEMBL31685351 | 0.76 | MEN1 (0.35) | CDAMAPTTK2 | |
| SCHEMBL31685169 | 0.73 | ADORA1 (0.39) | — | |
| SCHEMBL31685237 | 0.73 | CDA (0.43) | CDAMAPTPYGMTK2 | |
| SCHEMBL31685179 | 0.73 | UMPS (0.45) | — | |
| SCHEMBL114650 | 0.72 | LMNA (0.45) | CDAMAPTPYGMLMNAMTOR | |
| SCHEMBL31685392 | 0.72 | LMNA (0.43) | CDAMAPTPYGMLMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630985-B1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | ARCTURUS THERAPEUTICS INC (US) | 2025-08-27 | — | — | EP | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4602052-A1 | PROTEIN-BASED SIGNAL AMPLIFICATION | California Institute of Technology (US) | 2025-08-20 | — | — | EP | claimed |
| WO-2025128901-A1 | CIRCULAR RNA MOLECULES | ARCTURUS THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025122628-A1 | CIRCULARIZED RNAS AND METHODS OF MAKING THE SAME | HELIX NANOTECHNOLOGIES INC (US) | 2025-06-12 | — | — | WO | claimed |
| EP-4558630-A1 | METHODS AND APPARATUS FOR DUPLEX NUCLEOTIDE PURIFICATION | Agilent Technologies, Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| WO-2025081087-A1 | METHODS FOR CENTRAL NERVOUS SYSTEM NUCLEIC ACID DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025081080-A1 | COMPOSITIONS FOR CENTRAL NERVOUS SYSTEM NUCLEIC ACID DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-3871696-B1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | TRANSLATE BIO INC (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2025024442-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BSEP DEFICIENCY | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2023086893-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | TRANSLATE BIO, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4146680-A1 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | Translate Bio, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2023023528-A1 | CELL-TO-CELL DELIVERY OF RNA CIRCUITS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2022204549-A1 | OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING THE EXTRACELLULAR DOMAIN OF HUMAN ACE2 PROTEIN OR A PORTION THEREOF | TRANSLATE BIO, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| EP-3587409-B1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO INC (US) | 2022-06-01 | — | — | EP | claimed |
| EP-3976115-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOCHROMATOSIS | Ultragenyx Pharmaceutical Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| CN-106795142-A | Stereochemically enriched compositions for delivery of nucleic acids | 夏尔人类遗传性治疗公司 | 2017-05-31 | — | — | CN | claimed |
| CN-105813656-A | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | 夏尔人类遗传性治疗公司 | 2016-07-27 | — | — | CN | claimed |
| CN-105658800-A | CNS delivery of MRNA and uses thereof | 夏尔人类遗传性治疗公司 | 2016-06-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | CDA 794/4885MAPT 1540/4885PYGM 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.